The ATNM chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ATNM chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The ATNM stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View ATNM Detailed Price Forecast - CNN Money||View ATNM Detailed Summary - Google Finance|
|View ATNM Detailed Summary - Yahoo! Finance||View ATNM Stock Research & Analysis - Zacks.com|
|View ATNM Trends & Analysis - Trade-Ideas||View ATNM Major Holders - Barrons|
|View ATNM Call Transcripts - NASDAQ||View ATNM Breaking News & Analysis - Seeking Alpha|
|View ATNM Annual Report - CompanySpotlight.com||View ATNM OTC Short Report - OTCShortReport.com|
|View ATNM Fundamentals - TradeKing||View ATNM SEC Filings - Bar Chart|
|View Historical Prices for ATNM - The WSJ||View Performance/Total Return for ATNM - Morningstar|
|View the Analyst Estimates for ATNM - MarketWatch||View the Earnings History for ATNM - CNBC|
|View the ATNM Earnings - StockMarketWatch||View ATNM Buy or Sell Recommendations - MacroAxis|
|View the ATNM Bullish Patterns - American Bulls||View ATNM Short Pain Metrics - ShortPainBot.com|
|View ATNM Stock Mentions - StockTwits||View ATNM Stock Mentions - PennyStockTweets|
|View ATNM Stock Mentions - Twitter||View ATNM Investment Forum News - Investor Hub|
|View ATNM Stock Mentions - Yahoo! Message Board||View ATNM Stock Mentions - Seeking Alpha|
|View Insider Transactions for ATNM - SECform4.com||View Insider Transactions for ATNM - Insider Cow|
|View ATNM Major Holdings Summary - CNBC||View Insider Disclosure for ATNM - OTC Markets|
|View Insider Transactions for ATNM - Yahoo! Finance||View Institutional Holdings for ATNM - NASDAQ|
|View ATNM Stock Insight & Charts - FinViz.com||View ATNM Investment Charts - StockCharts.com|
|View ATNM Stock Overview & Charts - BarChart||View ATNM User Generated Charts - Trading View|
Actinium Pharmaceuticals to Participate in the Oppenheimer & Co. Fall Summit Focused on Specialty Pharma and Rare Disease
Posted on Thursday September 20, 2018
NEW YORK , Sept. 20, 2018 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) today announced that the Company will participate in the Oppenheimer & Co. Fall Summit Focused on Specialty ...
Should You Worry About The Actinium Pharmaceuticals Inc’s (NYSEMKT:ATNM) Shareholder Register?
Posted on Tuesday September 18, 2018
A look at the shareholders of Actinium Pharmaceuticals Inc (NYSEMKT:ATNM) can tell us which group is most powerful. Generally speaking, as a company grows, institutions will increase their ownership. Conversely,Read More...
Actinium Pharmaceuticals to Host Webinar Showcasing New Pipeline Initiative Focused on the CAR-T Space
Posted on Tuesday September 18, 2018
NEW YORK, Sept. 18, 2018 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or "the Company"), announced today that it will unveil a new clinical initiative that expands the Company's pipeline into the CAR-T space. CAR-T is a type of cellular therapy that genetically alters a patient's own T cells to target and kill their cancer cells.
Actinium Appoints Robert N. Daly, Ph.D. to Newly Created Role of Vice President, Head of Clinical Operations
Posted on Thursday September 06, 2018
NEW YORK, Sept. 6, 2018 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) today announced the appointment of Robert N. Daly, M.S., Ph.D., to the position of Vice President, Head of Clinical Operations, effective immediately. In this role, Dr. Daly will oversee all clinical operations, with a focus on executing Actinium's progressing pivotal Phase 3 trial for Iomab-B as a targeted conditioning agent, driving forward the Company's growing CD33 program including its advancement in targeted conditioning, as well as future clinical trial expansion for the entire pipeline.